Demande de RDV
Venir à l'ICM
Faire un don
Our ambition is to build a new oncology research facility. This new building, located at the heart of MedVallée—the health innovation ecosystem led by Montpellier Méditerranée Métropole—will aim to accelerate the transfer of therapeutic innovation to patients, supporting multidisciplinary research efforts.
Designed as an accelerator of medical innovation, the CTIO positions itself at the interface between scientific research conducted at the Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194) and its clinical application. Its goal: to foster the rapid development of research for the direct benefit of patients.
The CTIO will be the true missing link in oncology research, creating essential synergies between academic actors and the business world, all driven by a single purpose: to inspire and quickly transfer innovations to patients. Our vision of a true Montpellier Cancer Cluster with international influence is taking shape. The future of oncology is also being written in Montpellier!
Pr Marc Ychou – General Director of ICM
A hub at the interface between Science and Care
The building, designed by the MDR Architecture firm, will provide an environment dedicated to Translational Research, bringing together expertise and technology in synergy.
It will integrate platforms dedicated to the development and validation of tissue and circulating biomarkers for cancer diagnosis, prognosis, prediction of treatment response, and toxicity assessment. Additionally, it will house a new computational biology center aimed at enhancing analytical capacities for large-scale cancer research data.
The Center for Transfer and Innovation in Oncology will be built on a site dedicated to the MedVallée project, near the ICM campus, extending the existing buildings of the Institut de Recherche en Cancérologie de Montpellier (IRCM U1194).
Estimated area:
- Total building area: 1,500 m² over 3 levels
- Land area: 2,637 m²
Projected timeline:
- Expected delivery: First half of 2028
A strong foundation in a tradition of excellence in oncology
Building on the momentum of SIRIC Montpellier Cancer—certified since 2012 and the only site in southern France to hold this status of excellence—the CTIO reinforces Montpellier’s strategic position on the international oncology research stage.
It fully aligns with a shared ambition: to structure, unite, and expand Montpellier’s thriving ecosystem of health innovation.
A unique scientific ecosystem, creating economic value
A hub for scientific collaboration and exchange, the CTIO will be an open space for the economic sector, welcoming partner companies committed to developing and enhancing innovative technologies in oncology.
This close connection between academic research and industrial innovation will enable the rapid transfer of discoveries into concrete applications—Artificial Intelligence, alphatherapy, and therapeutic antibodies—further strengthening the competitiveness of the Montpellier region.
Funding: The estimated cost of the CTIO project is €7.7M, with financial support from:
- The State: €2M
- The Occitanie Region - FEDER funds: €2M
- Montpellier Méditerranée Métropole: €1M
- Inserm: €330K
- University of Montpellier: €200K
- Institut du Cancer de Montpellier (ICM): €2.2M
The ICM intends to launch a donation campaign to contribute to the project's funding.